Richard T. Hoppe

Q: What Schools Are Affiliated With Richard T. Hoppe

Richard T. Hoppe is affiliated with the following schools: University of California, Berkeley, University of Cologne, University of Arizona, Stanford University, University of Rochester

Richard T. Hoppe's AcademicInfluence.com Rankings

Richard T. Hoppe

Computer Science

#3908

World Rank

#4107

Historical Rank

Computational Linguistics

#281

World Rank

#285

Historical Rank

Machine Learning

#609

World Rank

#616

Historical Rank

Artificial Intelligence

#811

World Rank

#824

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Richard T. Hoppe's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Richard T. Hoppe Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard T. Hoppe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised response criteria for malignant lymphoma. (2007) (4137)
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. (1999) (3170)
Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. (1993) (749)
Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. (2003) (604)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. (2016) (514)
Tolerance and chimerism after renal and hematopoietic-cell transplantation. (2008) (491)
Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). (2014) (450)
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. (2010) (434)
Cardiac disease following treatment of Hodgkin's disease in children and adolescents. (1993) (426)
European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. (2008) (412)
Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. (1996) (393)
Psychosocial problems among survivors of Hodgkin's disease. (1986) (375)
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. (2010) (355)
Female Reproductive Potential after Treatment for Hodgkin's Disease (1981) (354)
Central nervous system involvement in non‐Hodgkin's lymphoma: An analysis of 105 cases (1982) (327)
Protective conditioning for acute graft-versus-host disease. (2005) (323)
High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. (1997) (320)
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. (2002) (317)
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. (2015) (283)
Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. (1996) (278)
Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. (2015) (272)
CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. (2003) (272)
Breast Cancer After Treatment of Hodgkin's Disease (1993) (271)
The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. (1982) (264)
Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. (2006) (254)
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). (2013) (246)
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. (2013) (228)
Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy (1976) (223)
Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. (1997) (222)
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. (2015) (213)
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. (1998) (212)
Histologic conversion in the non-Hodgkin's lymphomas. (1983) (211)
How I treat mycosis fungoides and Sézary syndrome. (2009) (209)
Treatment of intractable rheumatoid arthritis with total lymphoid irradiation. (1981) (207)
Mixed chimerism and immunosuppressive drug withdrawal after hla-mismatched kidney and hematopoietic progenitor transplantation1 (2002) (207)
Hodgkin's disease: complications of therapy and excess mortality. (1997) (207)
Hodgkin's Disease: A clinicopathologic study of 659 cases (1982) (205)
Electron-beam therapy for mycosis fungoides: the Stanford University experience. (1979) (199)
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. (2003) (193)
Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. (1995) (191)
The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. (1981) (189)
Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. (1989) (186)
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. (2012) (184)
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. (2006) (184)
Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. (2003) (175)
Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. (1995) (173)
CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. (1995) (170)
Hodgkin disease: contributions of chest CT in the initial staging evaluation. (1986) (164)
Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation (2015) (163)
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. (2009) (162)
Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. (1999) (161)
Analysis of non‐Hodgkin's lymphomas with nodular and favorable histologies, stages I and II (1983) (161)
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. (2001) (156)
Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. (2001) (147)
Non‐hodgkin's lymphoma. A study of the evolution of the disease based upon 92 autopsied cases (1979) (146)
Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin disease. (1984) (143)
Allograft Tolerance after Total Lymphoid Irradiation (TLI) (1979) (140)
Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. (2015) (139)
Non-Hodgkin's lymphomas of head and neck extranodal sites. (1985) (138)
Electron beam treatment for cutaneous T-cell lymphoma. (1995) (137)
Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment. (1990) (137)
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status (2016) (135)
Management of breast cancer after Hodgkin's disease. (2000) (134)
Non‐hodgkin's lymphomas (2010) (133)
Non-Hodgkin's lymphomas, version 4.2014. (2014) (131)
Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. (1988) (131)
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. (2016) (127)
Psychosocial outcomes of cancer: a comparative analysis of Hodgkin's disease and testicular cancer. (1993) (126)
Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. (2015) (125)
Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. (1988) (123)
Mycosis fungoides: management with topical nitrogen mustard. (1987) (122)
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (122)
Autologous mixed lymphocyte reaction in patients with Hodgkin's disease. Evidence for a T cell defect. (1980) (121)
Primary radiotherapy for localized orbital MALT lymphoma. (2002) (120)
Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. (1994) (120)
Leu-8 and Leu-9 antigen phenotypes: immunologic criteria for the distinction of mycosis fungoides from cutaneous inflammation. (1986) (120)
Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. (2000) (120)
Clonal rearrangements of immunoglobulin genes and progression to B cell lymphoma in cutaneous lymphoid hyperplasia. (1989) (119)
Solitary plasmacytoma of bone: treatment, progression, and survival. (1987) (116)
Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. (1989) (115)
Cutaneous malignant lymphoma: A pathologic study of 50 cases with clinical analysis of 37 (1981) (113)
Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. (1999) (109)
The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. (2011) (108)
The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. (1988) (107)
Extralymphatic involvement in diffuse non-Hodgkin's lymphoma. (1983) (106)
Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values. (1990) (105)
The rationale for curative radiotherapy in mycosis fungoides. (1977) (105)
Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. (2009) (104)
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 (2013) (103)
Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. (1987) (102)
Detection of clonal T-cell receptor gene rearrangements in the peripheral blood of patients with mycosis fungoides/Sezary syndrome. (1989) (101)
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. (2012) (100)
Mycosis fungoides and the Sézary syndrome. (1999) (99)
Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. (1990) (98)
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. (2014) (98)
Hodgkin's disease in homosexual men with generalized lymphadenopathy. (1985) (98)
Mycosis fungoides: radiation therapy (2003) (98)
High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. (1996) (97)
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. (2018) (96)
Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma. (2013) (94)
Non‐Hodgkin's lymphoma. Involvement of Waldeyer's ring (1978) (92)
A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. (2009) (92)
Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides. (1986) (91)
Radiation therapy in the management of cutaneous T-cell lymphomas. (1979) (91)
Revisiting low-dose total skin electron beam therapy in mycosis fungoides. (2011) (91)
T-cell antigen deficiencies and clonal rearrangements of T-cell receptor genes in pagetoid reticulosis (Woringer-Kolopp disease). (1988) (90)
Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. (1994) (90)
Prognostic factors in pathological stage IIIA Hodgkin's disease (1980) (89)
Induction of specific unresponsiveness to heart allografts in mongrel dogs treated with total lymphoid irradiation and antithymocyte globulin. (1984) (89)
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. (2013) (88)
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium (2017) (87)
Mycosis fungoides in young patients: clinical characteristics and outcome. (1998) (84)
Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. (1988) (82)
Treatment of intractable lupus nephritis with total lymphoid irradiation. (1985) (81)
Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. (1991) (81)
Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. (2006) (79)
Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. (1997) (79)
Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma (2013) (78)
Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. (1995) (77)
Carcinoma of the nasopharynx--the significance of histology. (1978) (77)
Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. (2019) (77)
Diffuse Large B-Cell Lymphoma Version 1.2016. (2016) (76)
Efficacy of total lymphoid irradiation in intractable rheumatoid arthritis. A double-blind, randomized trial. (1985) (76)
Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. (1997) (75)
Gene expression profiles of cutaneous B cell lymphoma. (2003) (75)
Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. (1987) (72)
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. (2001) (72)
Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. (2007) (72)
Non-Hodgkin's lymphomas, version 1.2013. (2013) (71)
Hodgkin's disease in patients over sixty years old. (1984) (71)
Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. (2013) (71)
Mycosis fungoides: Clinical and histologic features, staging, evaluation, and approach to treatment (1993) (70)
Subtypes of cutaneous T-cell lymphoma defined by expression of leu-1 and Ia. (1982) (69)
The role of radiation therapy in the management of stage III follicular lymphomas. (1984) (69)
Transformation of mycosis fungoides: T-cell receptor beta gene analysis demonstrates a common clonal origin for plaque-type mycosis fungoides and CD30+ large-cell lymphoma. (1993) (69)
Long-term depletion of naive T cells in patients treated for Hodgkin's disease. (1997) (69)
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (68)
Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. (1996) (67)
Discordant expression of antigens between intraepidermal and intradermal T cells in mycosis fungoides. (1990) (67)
The long term effects of radiation on T and B lymphocytes in the peripheral blood after regional irradiation (1977) (66)
PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study. (1987) (66)
Gastrointestinal cancer after treatment of Hodgkin's disease. (1997) (66)
Sézary syndrome: a model for migration of T lymphocytes to skin. (1980) (66)
Morphologic types of diffuse large‐cell lymphoma (1982) (65)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome (2015) (64)
Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease. (1987) (64)
Prognostic factors in pathologic stage III Hodgkin's disease. (1982) (64)
The Janeway lecture. Hodgkin's disease--finding the balance between cure and late effects. (1999) (63)
Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. (1996) (63)
The role of radiation therapy in the management of the non‐Hodgkin's lymphomas (1985) (63)
The management of extranodal head and neck lymphomas. (1986) (62)
Mycosis fungoides skin lesions contain CD8+ tumor‐infiltrating lymphocytes expressing an activated, MHC‐restricted cytotoxic T‐lymphocyte phenotype (1994) (61)
Lymph node biopsy in mycosis fungoides (1981) (61)
Leibel and Phillips textbook of radiation oncology (2010) (60)
Late relapse among patients treated for Hodgkin's disease. (1985) (60)
Small lymphocytic lymphoma. (1989) (59)
Benign and malignant forms of erythroderma: cutaneous immunophenotypic characteristics. (1988) (59)
Sustained improvement of intractable rheumatoid arthritis after total lymphoid irradiation. (1983) (58)
Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long‐term survivors of Hodgkin's disease: July 9–16, 2003, Bellagio, Italy (2005) (58)
Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. (2017) (58)
Expression of T-cell receptor antigens in mycosis fungoides and inflammatory skin lesions. (1989) (58)
Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis Fungoides (2001) (58)
Changes in marital and sexual functioning in long‐term survivors and their spouses: Testicular cancer versus hodgkin's disease (1992) (57)
PUVA treatment of erythrodermic and plaque type mycosis fungoides. (1981) (57)
How I treat mycosis fungoides and Sézary syndrome. (2016) (56)
Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin's disease (1979) (56)
Poikilodermatous mycosis fungoides and atrophic large-plaque parapsoriasis exhibit similar abnormalities of T-cell antigen expression. (1988) (55)
Hodgkin lymphoma (2020) (55)
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. (2018) (54)
Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. (1996) (54)
Radiation therapy in the management of Hodgkin's disease. (1990) (53)
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. (2018) (51)
Radiosensitivity in vitro of human fibroblasts derived from patients with a severe skin reaction to radiation therapy. (1980) (51)
Recovery of spermatogenesis following pelvic irradiation for Hodgkin's disease. (1986) (51)
Lymphocyte predominant Hodgkin's disease: clinical presentation and results of treatment. (1984) (51)
Radiation therapy in the treatment of Hodgkin's disease. (1980) (51)
MR imaging to detect chest wall and pleural involvement in patients with lymphoma: effect on radiation therapy planning. (1993) (51)
Ointment‐based mechlorethamine treatment for mycosis fungoides (1983) (50)
Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era (2015) (49)
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. (1991) (49)
Long-term followup of rheumatoid arthritis patients treated with total lymphoid irradiation. (1987) (49)
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. (2007) (49)
Effects of Treatment on the Work Experiences of Long-Term Survivors of Hodgkin's Disease (1989) (49)
Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. (2001) (48)
Population parameters and philopatry of breeding female wood ducks (1987) (48)
Woringer-Kolopp disease (pagetoid reticulosis). Four cases with histopathologic, ultrastructural, and immunohistologic observations. (1984) (48)
Hodgkin's disease limited to intrathoracic sites (2006) (48)
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. (1997) (47)
Hodgkin's disease at autopsy: 1972–1977 (1981) (47)
NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines (2017) (47)
Clonal rearrangement of the T cell receptor beta gene in the circulating lymphocytes of erythrodermic follicular mucinosis. (1988) (47)
Outcome of the acute glomerular injury in proliferative lupus nephritis. (1989) (46)
How I treat nodular lymphocyte predominant Hodgkin lymphoma. (2013) (46)
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. (2006) (46)
Total skin electron beam therapy in the management of mycosis fungoides. (1991) (46)
Non-Hodgkin's lymphomas, version 2.2014. (2014) (46)
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. (2015) (46)
The treatment of mycosis fungoides. Adjuvant topical mechlorethamine after electron beam therapy (1977) (45)
Changes in T-cell subsets in patients with rheumatoid arthritis treated with total lymphoid irradiation. (1983) (45)
Expression of the bcl‐6 and MUM1/IRF4 proteins correlate with overall and disease‐specific survival in patients with primary cutaneous large B‐cell lymphoma: a tissue microarray study (2005) (45)
Expression of Leu-8 antigen, a majority T-cell marker, is uncommon in mycosis fungoides. (1985) (44)
TREATMENT OF CADAVERIC RENAL TRANSPLANT RECIPIENTS WITH TOTAL LYMPHOID IRRADIATION, ANTITHYMOCYTE GLOBULIN, AND LOW-DOSE PREDNISONE (1985) (44)
Hodgkin lymphoma, version 2.2015. (2015) (44)
Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. (2004) (44)
Cutaneous lymphoid hyperplasia. Immunologic characteristics and assessment of criteria recently proposed as diagnostic of malignant lymphoma. (1989) (44)
Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University. (2001) (44)
Subspecialization in radiology and radiation oncology. (2009) (44)
CLINICAL AND IMMUNOLOGICAL STUDIES OF CADAVERIC RENAL TRANSPLANT RECIPIENTS GIVEN TOTAL‐LYMPHOID IRRADIATION AND MAINTAINED ON LOW‐DOSE PREDNISONE (1988) (43)
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. (2020) (43)
Non‐hodgkin's lymphoma presenting as thyroid enlargement (1981) (42)
Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease (2012) (42)
Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. (2008) (42)
Engraftment of allogeneic bone marrow without graft-versus-host disease in mongrel dogs using total lymphoid irradiation. (1980) (42)
The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiotherapy Era. (2020) (42)
Subdiaphragmatic Hodgkin's disease: laparotomy and treatment results in 49 patients. (1987) (41)
Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy. (1993) (41)
Survival of primates following orthotopic cardiac transplantation treated with total lymphoid irradiation and chemical immune suppression. (1981) (41)
Transplantation of bone marrow in outbred dogs without graft-versus-host disease using total lymphoid irradiation. (1979) (41)
Total lymphoid irradiation for treatment of intractable cardiac allograft rejection. (1991) (40)
Progress in the treatment of Hodgkin's disease in the United States, 1973 versus 1983. The patterns of care study (1994) (40)
Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease. (2008) (39)
Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin’s Disease (NLPHD). (2007) (37)
Dissection of the mechanisms of immune injury in rheumatoid arthritis, using total lymphoid irradiation. (1988) (37)
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. (2018) (37)
Physical Performance at work and at Leisure (1990) (37)
Combined modality therapy for stage I-II large cell lymphoma. (1987) (36)
Cardiac allograft survival in rhesus primates treated with combined total lymphoid irradiation and rabbit antithymocyte globulin. (1979) (36)
Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin (2009) (36)
Transplantation tolerance after total lymphoid irradiation. (1979) (35)
Non-Hodgkin lymphoma: influence of lymphography, CT, and bone marrow biopsy on staging and management. (1989) (34)
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. (2006) (33)
Organ transplantation in mongrel dogs using total lymphoid irradiation (TLI). (1981) (32)
Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkin’s Disease: Mature Data in Early and Advanced Stage Patients. (2004) (31)
A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496) (2010) (31)
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. (2009) (31)
Stage IIB Hodgkin's disease: the Stanford experience. (1986) (31)
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. (2015) (31)
The management of stage II Hodgkin's disease with a large mediastinal mass: a prospective program emphasizing irradiation. (1985) (31)
The treatment of mycosis fungoides with ointment-based mechlorethamine. (1982) (30)
Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines (2012) (29)
The management of mycosis fungoides at Stanford--standard and innovative treatment programmes. (1991) (29)
Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. (2013) (29)
Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression (2012) (28)
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations (2017) (28)
Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal (2020) (28)
Long-term results of total lymphoid irradiation in the treatment of cardiac allograft rejection. (1997) (28)
Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. (1997) (28)
Topical mechlorethamine therapy for mycosis fungoides (1977) (27)
Effect of filgrastim (G-CSF) in Hodgkin's disease patients treated with radiation therapy. (1994) (26)
Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. (2014) (26)
Extranodal nonorbital indolent lymphomas of the head and neck: relationship between tumor control and radiotherapy. (2004) (26)
Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era. (2016) (26)
Lupus nephritis after total lymphoid irradiation: persistent improvement and reduction of steroid therapy. (1987) (26)
Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG) (2017) (26)
Paediatric primary cutaneous marginal zone B‐cell lymphoma: does it differ from its adult counterpart? (2017) (25)
What is the prognosis for patients who relapse after primary radiation therapy for early-stage low-grade follicular lymphoma? (1998) (25)
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. (2017) (25)
Treatment of lupus nephritis with total lymphoid irradiation. Observations during a 12-79-month followup. (1988) (23)
Long-term follow-up after total lymphoid irradiation in pediatric heart transplant recipients. (2002) (23)
Long‐term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma (2012) (23)
Role of histology in providing prognostic information in mycosis fungoides (1998) (22)
Hodgkin's disease. (1992) (22)
The treatment of intractable rheumatoid arthritis with lymphoid irradiation. (1981) (21)
Overview of treatment of localized low-grade lymphomas. (1997) (21)
Extracutaneous mycosis fungoides (1987) (20)
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. (2020) (20)
Treatment planning for Hodgkin's disease: a patterns of care study. (1995) (20)
Suppressor cells of the mixed lymphocyte reaction in patients with Hodgkin's disease. (1979) (19)
Experience with lymphography in patients with mycosis fungoides. (1979) (19)
Epidermotropic cutaneous B-cell lymphoma mimicking mycosis fungoides. (1999) (19)
The contemporary management of Hodgkin disease. (1988) (19)
NCCN: Non-Hodgkin's lymphoma. (2001) (19)
Follicular and diffuse mixed small-cleaved and large-cell lymphoma--a clinicopathologic study. (1985) (19)
Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. (2012) (18)
Expert radiation oncologist interpretations of involved-site radiation therapy guidelines in the management of Hodgkin lymphoma. (2015) (18)
Non-Hodgkin's Lymphomas, version 3.2012. (2012) (18)
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma (2021) (18)
Training the radiation oncologist for the twenty-first century. (1996) (18)
Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience. (2016) (18)
Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. (2021) (18)
Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma (2008) (18)
Development of effective salvage treatment programs for Hodgkin's disease: an ongoing clinical challenge [editorial] (1991) (17)
Subcutaneous mycosis fungoides. (1978) (17)
Early-stage Hodgkin's disease: a choice of treatments or a treatment of choice? (1991) (17)
Radiation therapy in the management of bulky mediastinal Hodgkin's disease (1990) (17)
Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. (2015) (17)
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (17)
Stage I-II Hodgkin's disease: current therapeutic options and recommendations. (1983) (17)
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. (2000) (16)
Treatment of Autoimmune Disease with Total Lymphoid Irradiation Cellular and Humoral Mechanisms (1986) (16)
Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG. (2020) (16)
Current Stanford clinical trials for Hodgkin's disease. (1989) (16)
Clinical Characteristics and Long-term Outcome of Patients With Generalized Patch and / or Plaque ( T 2 ) Mycosis Fungoides (1999) (16)
Survival in Follicular Lymphoma: The Stanford Experience, 1960–2003. (2007) (16)
Hodgkin disease/lymphoma. (2008) (16)
Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. (2020) (16)
Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. (2019) (15)
771 Is radiotherapy curative for stage I-II low-grade follicular lymphoma? (1995) (15)
Metastatic carcinoma in lymph nodes simulating "syncytial variant" of nodular sclerosing Hodgkin's disease. (1991) (15)
A single-institution retrospective analysis of outcomes for stage I–II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy (2016) (15)
Evolution of the techniques of radiation therapy in the management of lymphoma (2013) (15)
Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project. (1990) (15)
NCCN preliminary non-Hodgkin's lymphoma practice guidelines. (1997) (14)
Most CD8+ cells in skin lesions of CD3+ CD4+ mycosis fungoides are CD3+ T cells that lack CD11b, CD16, CD56, CD57, and human Hanukah factor mRNA. (1991) (14)
Original article: The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease (1992) (14)
Histologic variation in non-Hodgkin's lymphomas: commentary. (1981) (14)
Role of FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience. (2009) (14)
Radiotherapeutic Principles of Hematopoietic Cell Transplantation (2007) (14)
Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496 (2010) (14)
Hodgkin lymphoma. (2021) (14)
Cutaneous peripheral T-cell lymphoma associated with a proliferation of B cells. (2009) (13)
ACR White Paper: Task Force to Evaluate the Value Add Impact on Business Models. (2009) (13)
Partial orbit irradiation achieves excellent outcomes for primary orbital lymphoma. (2016) (13)
Role of imaging in low grade cutaneous B-cell lymphoma presenting in the skin. (2019) (13)
Spleen structure in Hodgkin disease: ultrasonic characterization. Work in progress. (1984) (13)
Results of the 1988-1989 Patterns of Care Study process survey for Hodgkin's disease. (1999) (13)
Nodular lymphoma. Clinicopathologic correlations of parafollicular small lymphocytes and degree of nodularity (1980) (13)
The management of bulky mediastinal Hodgkin's disease. (1989) (13)
Effect of diving ducks on benthic food resources during winter in South Carolina, U.S.A (1986) (13)
Breast cancer after treatment of Hodgkin's disease. (1993) (13)
Arthritis in a patient with mycosis fungoides: complete remission after radiotherapy. (1979) (12)
Immunosuppression and tolerance after total lymphoid irradiation (TLI). (1980) (12)
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. (2022) (12)
Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. (2011) (11)
What is the significance of nasal involvement in nasopharyngeal carcinoma? (1999) (11)
Short Tandem Repeat Analysis to Monitor Chimerism in Macaca Fascicularis (2004) (11)
Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. (2009) (11)
Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation (2017) (11)
The non-Hodgkin's lymphomas: pathology, staging, treatment. (1987) (11)
AIDS and Hodgkin's disease. (1985) (11)
OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF 18F‐FDG PET‐CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG (2017) (10)
Recommendations for revised response criteria for malignant lymphoma. (2006) (10)
Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. (2012) (10)
The management of Hodgkin's disease in relapse after primary radiation therapy. (1992) (10)
Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma (2014) (10)
Treatment of intractable rheumatoid arthritis with total lymphoid irradiation (TLI): immunological and clinical changes. (1983) (10)
Secondary leukemia and myelodysplastic syndrome after treatment for Hodgkin's disease. (1992) (10)
Hodgkin's disease--the role of radiation therapy in advanced disease. (1996) (10)
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. (2019) (10)
Use of total lymphoid irradiation (TLI) in bone marrow and organ transplantation. (1979) (9)
Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era. (2015) (9)
Total lymphoid irradiation in the management of autoimmune diseases and organ transplantation (1984) (9)
The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin's lymphomas. (1985) (9)
Maintenance of certification for radiation oncology. (2005) (9)
Report of the American Society for Therapeutic Radiology and Oncology Working Group on the scope of radiation oncology (SCOPE). (2002) (9)
Evidence that mycosis fungoides mf and transformed mf arise from the same t cell clone (1991) (8)
Treatment of early‐stage gastric lymphoma (1994) (8)
Heart disease mortality after treatment of Hodgkin's disease (1992) (8)
Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. (2019) (8)
Characterization of splenic structure in Hodgkin disease by using narrow-band filtration of backscattered ultrasound. (1989) (8)
A preliminary report of gonadal-sparing TBI using a VMAT technique. (2020) (8)
The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease. (1985) (8)
Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University. (2006) (8)
Radiation therapy as a component of high-dose salvage strategies in Hodgkin's disease. (1998) (8)
EXPRESSION OF CLASS II MAJOR HISTOCOMPATIBILITY ANTIGENS BY KERATINOCYTES IN CUTANEOUS T CELL LYMPHOMA (1994) (8)
Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496 (2011) (7)
Pelvic relapse following subtotal lymphoid irradiation in early stage Hodgkin's disease--an analysis of risk, management, and outcome. (1995) (7)
Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496. (2011) (7)
Treatment planning in the radiation therapy of Hodgkin's disease. (1987) (7)
Cellular mechanisms of tolerance after total lymphoid irradiation (TLI). (1981) (7)
Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sézary Syndrome (2020) (7)
Use of cardiac radiation therapy as bridging therapy to CAR‐T for relapsed pediatric B‐cell acute lymphoblastic leukemia (2020) (7)
Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. (2015) (7)
Post-treatment surveillance imaging in lymphoma. (2018) (6)
Response of mediastinal Hodgkin's disease to radiotherapy: rate of tumor regression not predictive of outcome. (1989) (6)
Bexarotene Is Highly Active in the Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma. (2005) (6)
The John Ultmann lecture – the role of radiation therapy in the treatment of Hodgkin's disease: past, present, and future (2005) (6)
Treatment strategies in limited stage follicular NHL. (2011) (6)
Bone marrow transplantation for hematologic malignancies: the Stanford experience. (1990) (6)
Effects of irradiation on the human immune system. (1989) (6)
A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT) (2016) (6)
Hodgkin's lymphoma: the role of radiation in the modern combined strategies of treatment. (2007) (5)
Assessment of Favorable (F) Versus Unfavorable (U) Early Stage Hodgkin’s Disease (HD); the Stanford V + Radiotherapy (RT) Experience. (2005) (5)
Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas. (2006) (5)
A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA (2017) (5)
Abbreviated 8-week chemotherapy (CT) plus involved node radiotherapy (INRT) for nonbulky stage I-II Hodgkin lymphoma: Preliminary results of the Stanford G5 Study. (2011) (5)
Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496 (2013) (5)
A prospective trial of involved field radiation (IFRT) + chemotherapy compared to extended field (EFRT) radiation for favorable Hodgkin disease: Survival differences and implications of mature follow-up for current combined modality therapy (2007) (5)
XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma (2015) (5)
Nodular lymphomas: involvement of epitrochlear nodes. (1978) (5)
Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. (2014) (5)
Leibel and Phillips Textbook of Radiation Oncology, 3rd edition (2011) (5)
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression (2014) (5)
Alternating chemotherapy and irradiation in advanced Hodgkin's disease (1984) (4)
Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs. (2019) (4)
2 Gy × 2 for palliative treatment of mantle cell lymphoma (2016) (4)
A step towards making VMAT TBI more prevalent:au- tomating the treatment planning process Automated VMAT TBI planning. (2021) (4)
Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging (2015) (4)
Development of effective salvage treatment programs for Hodgkin's disease: an ongoing clinical challenge. (1991) (4)
Eli J. Glatstein: A Steward Extraordinaire of Radiation Oncology. (2020) (4)
Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience (2011) (4)
Long-term outcomes of patients with unfavorable stage I–II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation (2020) (3)
The Stanford VMAT TBI Technique. (2022) (3)
Treatment of early-stage gastric lymphoma. (1994) (3)
Waterfowl of the Savannah River Plant: Comprehensive cooling water study. Final report (1986) (3)
Induction of transplantation tolerance after total lymphoid irradiation: cellular mechanisms. (1981) (3)
Favorable Outcome in Stage I-II Mantle Cell Lymphoma: A Report of 160 Patients From the International Lymphoma Radiation Oncology Group (ILROG) (2014) (3)
Volumetric modulated arc therapy total body irradiation in pediatric and adolescent/young adult patients undergoing stem cell transplantation: Early outcomes and toxicities (2022) (3)
Low-Dose Radiation Therapy (2 Gy x 2) in the Treatment of Non-Hodgkin Lymphoma of the Ocular Adnexa (2013) (3)
Long-Term Outcomes of Patients with Early-Stage Non-Bulky Hodgkin Lymphoma Treated with Combined Modality Therapy on the Stanford V Trials (The G4 and G5 Studies). (2020) (3)
Little Blue Herons nesting among cattails (1986) (3)
The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease. (1992) (3)
Either Combined-Modality Or Radiotherapy Alone Provide Favorable Outcome In Stage I-II Mantle Cell Lymphoma: A Report Of 82 Patients From The International Lymphoma Radiation Oncology Group (ILROG) (2013) (3)
A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma (2017) (3)
Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003 (2008) (2)
Principles of Radiation Techniques in Hodgkin Lymphoma (2011) (2)
The definitive management of limited and intermediate stages of Hodgkin’s disease with radiation therapy alone (1983) (2)
Cardiac allograft survival in rhesus primates treated with total lymphoid irradiation and rabbit antithymocyte globulin. (1979) (2)
Are Advanced Radiation Therapy Technologies Required for Treating Patients With Hodgkin Lymphoma? (2016) (2)
Bulky mediastinal classical Hodgkin lymphoma in young women. (2014) (2)
82 Primary radiotherapy is curative for CS IE orbital MALT lymphoma (1997) (2)
145 Detection of relapse in early stage Hodgkin's disease: Role of routine follow up studies (1995) (2)
Follow-up of Hodgkin's disease. American College of Radiology. ACR Appropriateness Criteria. (2000) (2)
Confirmation of the prognostic value of the EORTC/WHO classification of primary cutaneous B-cell lymphoma in the United States: The Stanford University experience (2007) (2)
T-Cell Lymphomas, Version 2.2022 (2022) (2)
Hodgkin's disease: a model for interdisciplinary cancer management: 2002 Janeway lecture. (2002) (2)
Long-Term Outcomes in 10-Year Survivors of Early-Stage Hodgkin Lymphoma. (2019) (2)
Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS) (2014) (2)
TU-CD-304-01: FEATURED PRESENTATION and BEST IN PHYSICS (THERAPY): Trajectory Modulated Arc Therapy: Development of Novel Arc Delivery Techniques Integrating Dynamic Table Motion for Extended Volume Treatments (2015) (2)
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Hodgkin Lymphoma, Version 2.2020 (2020) (2)
Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma (2016) (2)
Radiotherapy planning for the lymphomas: expanding roles for biologic imaging. (2011) (2)
Tomayto, tomahto: prescription dose and mean heart dose in evaluating the cardiac impact of involved-field radiation therapy for Hodgkin lymphoma survivors (2019) (2)
Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma: Analysis of the Stanford Series Reveals Two Clinical Subsets of Patients. (2004) (2)
Prevention of allograft rejection by induction of specific transplantation tolerance with immunomanipulation using total lymphoid irradiation. (1980) (2)
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease. (2009) (2)
Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. (2018) (2)
A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies. (2005) (2)
Marked Improvement in Staging Accuracy in Mycosis Fungoides/Sézary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography (PET/CT). (2004) (2)
Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. (2018) (2)
Technical report: 3D-printed patient-specific scalp shield for hair preservation in total skin electron beam therapy (2021) (2)
TU-CD-304-01: FEATURED PRESENTATION and BEST IN PHYSICS (THERAPY): Trajectory Modulated Arc Therapy: Development of Novel Arc Delivery Techniques Integrating Dynamic Table Motion for Extended Volume Treatments (2015) (2)
Hodgkin Lymphoma Version 1 . 2017 Clinical Practice Guidelines in Oncology (2017) (2)
Non-Hodgkin’s Lymphomas, Version 4.2014: Clinical Practice Guidelines in Oncology (2014) (2)
Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era. (2014) (2)
Stage I/II Hodgkin’s Disease: Comparison of Outcomes of Patients with Bulky Mediastinal Disease Versus Other Risk Factors; the Stanford V Experience. (2007) (1)
Role of the spleen in the transdiaphragmatic spread of Hodgkin's disease. (1987) (1)
Cardiovascular mortality following treatment of Hodgkin's disease (1989) (1)
Sarah S. Donaldson, MD, President, Radiological Society of North America, 2013 (2013) (1)
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (2019) (1)
The Paris conference "La Radiothérapie de la Maladie de Hodgkin": a first step in the cure of Hodgkin disease. (2015) (1)
Chimerism and Tolerance after Combined Human Kidney and Hematopoietic Cell Transplantation Using Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin. (2008) (1)
Prognostic significance of CD15 expression in classical Hodgkin lymphoma (cHL): The Stanford University experience. (2010) (1)
20 Gy Versus 30 Gy: Will it Make a Difference? (2019) (1)
DOSE AND/OR VOLUME REDUCTION USING CONSOLIDATION VOLUME RADIATION THERAPY (CVRT) LOWERS DOSE TO HEART AND LUNGS IN EARLY‐STAGE HODGKIN LYMPHOMA PATIENTS WITH BULKY DISEASE (2017) (1)
Comment on: "clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 Study)". (2014) (1)
Successful murine tumor allotransplantation after total lymphoid irradiation. (1982) (1)
STAGE I‐II NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA IN THE MODERN ERA: A MULTI‐INSTITUTIONAL EXPERIENCE OF ADULT PATIENTS BY ILROG (2019) (1)
Variable Interpretations by Experienced Radiation Oncologists of Involved-Site Radiation Therapy Guidelines for Lymphoma (2014) (1)
The treatment of stage III – IV non-Hodgkin'S lymphoma of “favorable” histologic type. A randomized comparison of whole body irradiation, combination chemotherapy, and single agent chemotherapy (1979) (1)
Stage I–II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy (2021) (1)
Combined-Modality Therapy for the Treatment of Hodgkin’s Disease1 (1992) (1)
A Cutaneous Lymphoma International Consortium ‘CLIC’ study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging (2014) (1)
In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study (2010) (1)
Defining Clinical Target Volume in Patients with Early Stage Indolent Lymphoma Treated with Definitive Radiotherapy (2019) (1)
Low-dose total skin electron beam therapy for refractory cutaneous CD30 positive lymphoproliferative disorders (2021) (1)
A tribute to Malcolm A. Bagshaw--an innovative physician who soared to success. (2012) (1)
Remarkable Advances in the Management of Mycosis Fungoides and the Sezary Syndrome (2017) (1)
The Relationship of Mean Heart Dose and Cardiac Substructure Dose over Evolving Radiation Techniques in Mediastinal Lymphoma (2018) (1)
The Non-Hodgkin Lymphoma Pathologic Classification Project (2020) (1)
in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses (2012) (1)
Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years (2012) (1)
Relationship Between Mixed Chimerism and Acceptance of HLA-matched and -Mismatched Kidney Transplants after Withdrawal of Immunosuppressive Drugs (2018) (1)
Discordant Expression ofAntigens Between Intraepidermal andIntradermal TCells inMycosis Fungoides (1990) (1)
Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study. (2020) (1)
Stage III and IV Hodgkin's disease treatment guidelines. American College of Radiology. ACR Appropriateness Criteria. (2000) (1)
Staging evaluation for patients with Hodgkin's disease. American College of Radiology. ACR Appropriateness Criteria. (2000) (1)
Pediatric Hodgkin's disease. American College of Radiology. ACR Appropriateness Criteria. (2000) (1)
183 Cutaneous lymphoma international consortium (CLIC): Uniting worldwide experts to develop and validate a prognostic index model (2016) (0)
the Stanford University Results and Prognostic Indices of Transplantation for Recurrent or Refractory Hodgkin's Disease: Analysis High-Dose Therapy and Autologous Hematopoietic Progenitor Cell (2013) (0)
Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation (2021) (0)
Role of radiation therapy (2010) (0)
60 – Hodgkin's Disease (2010) (0)
Staging and prognosis (2019) (0)
Background and Rationale for Radiotherapy in Advanced-Stage Hodgkin Lymphoma (2011) (0)
Keep the Dose Low. Keep the Fields Tight. (2020) (0)
Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2 (2022) (0)
Analysis of Breast Cancer Subtypes in Women who Develop Breast Cancer following Mantle Irradiation for Hodgkin's Disease (2010) (0)
Author Correction: Hodgkin lymphoma (2021) (0)
Prognostic Factors and Patterns of Failure in Advanced Stage Hodgkin Lymphoma Treated with Stanford V and Radiation Therapy (2018) (0)
LYMPHATIC SYSTEM: Lymph node biopsy in mycosis fungoides (1981) (0)
Modern radiation therapy for hodgkin lymphom-target definition and dose guidelines from the international lymphoma radiation oncology group (2017) (0)
How I Treat How I treat mycosis fungoides and Sézary syndrome (2009) (0)
Salvage therapy and prognostic factors for patients (PTS) relapsing following radiotherapy for stage I, II, and IIIA/B Hodgkin's disease (HD) (1986) (0)
Total Lymphoid Irradiation in Renal Transplantation: Reduction and Elimination of Maintenance Immunosuppressive Drugs (1984) (0)
The NCCN Non-Hodgkin ’ s Lymphomas Clinical Practice Guidelines in OncologyTM (2010) (0)
Long-Term Outcomes For Stage I-II Diffuse Large B-Cell Lymphoma Treated With Rituximab And Chemotherapy With Or Without Radiotherapy (2020) (0)
2 Gy x 2 for Palliation of Indolent Mantle Cell Lymphoma (2015) (0)
Non-Hodgkin's LymphomasPractice Guidelines in Oncology TM (2010) (0)
Acceptance of bone marrow and organ allogorafts after total lymphoid irradiation (tli). Abstr. (1980) (0)
Non-Hodgkin’s Lymphomas (1999) (0)
The patterns of care study consensus review (1991) (0)
OP30 Role of radiation therapy in treating Hodgkin's disease (2007) (0)
Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Clinical and Molecular Characterization of a Subset with Worse Outcome. (2007) (0)
Impact of Myc-Altered Pathology on Radiotherapy Efficacy among Patients with Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Retrospective Study (2022) (0)
Plain language summaries in Simplified Chinese (2017) (0)
Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma (2022) (0)
Larry Emanuel Kun, March 10, 1946-May 27, 2018. (2019) (0)
Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant (2021) (0)
Consolidative Radiation Therapy Following Autologous Stem Cell Transplant in Relapsed or Refractory Hodgkin Lymphoma (2020) (0)
Outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the pre- and post-rituximab era: The Stanford University experience. (2011) (0)
Biological characterization of stage I follicular lymphoma according to extranodal or nodal primary origin and t(14;18) status using high‐resolution array‐based comparative genomic hybridization (2015) (0)
Intercurrent death following Hodgkin's disease therapy: radiotherapy, adjuvant mopp trials (1987) (0)
Impact of Testicular Boost on Oncologic Outcomes and Late Effects in Pediatric Patients With Leukemia Receiving Fractionated Total Body Irradiation (TBI): A Single-Institution Experience. (2021) (0)
Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort (2018) (0)
63 – Plasma Cell Tumors: Multiple Myeloma And Solitary Plasmacytoma (2010) (0)
‘ ‘ focus on . . . ’ ’ session : transformation 086 SNP ARRAY GENOTYPING IN 182 DIAGNOSTIC FOLLICULAR LYMPHOMA CASES IDENTIFIES SITES OF AUPD ASSOCIATED WITH OVERALL SURVIVAL AND RISK OF TRANSFORMATION (2008) (0)
Chapter 25 – Primary Cutaneous Lymphomas (2006) (0)
3001 The internet radiation oncology journal club — A multi-institutional collaborative education project (1997) (0)
An Evaluation Of Abdominal Ct Scanning In Initial Staging Of Hodgkin's And Non-hodgkin's Lymphoma: Progress Report (1981) (0)
In Situ Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions (2021) (0)
AbstractEfficacy and side effects of total lymphoid irradiation (TLI) in severe rheumatoid arthritis and lupus nephritis. Risk of malignancy after the use of TLI in Hodgkin's disease with and without chemotherapy (1986) (0)
Definitive and Immediate Salvage Treatment Achieves Durable Response for Relapse Following Primary RT for Follicular Lymphoma: An International Collaborative Study on Behalf of ILROG (2018) (0)
Presentation, treatment and survival of patients experiencing first relapse of stage I and II low grade or follicular non-hodgkin's lymphoma (1991) (0)
Laparotomy and treatment results of 49 patients with subdiaphragmatic Hodgkin's disease (1986) (0)
Improved tumor control with irradiation to the primary site in extranodal non-orbital indolent lymphomas of the head and neck (2003) (0)
Effect of Testicular Boost in Children With Leukemia Receiving Total Body Irradiation and Stem Cell Transplant: A Single-Institution Experience (2022) (0)
A dosimetric comparison of conventional and intensity modulated radiation therapies for the treatment of hodgkin’s disease (2002) (0)
Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen (2010) (0)
Investigating Gene Expression Phenotypes and Tumor Microenvironment Factors Associated with Response to Low Dose Radiotherapy for Follicular Lymphoma (2022) (0)
Introduction to Hematologic Malignancies (2017) (0)
24. Primary Cutaneous B-Cell Lymphoma (2003) (0)
Evaluation of Radiation Therapy for NK-T-cell Lymphoma of the Head and Neck (2012) (0)
Use of Total Lymphoid Irradiation in Organ Transplantation (1985) (0)
100 President's categorical course on lymphoma (1997) (0)
Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease (2010) (0)
Primary Treatment Classical Hodgkin Lymphoma : Lymphocyte-predominant Hodgkin Lymphoma : NCCN Hodgkin Disease / Lymphoma Panel Members Summary of Guidelines Updates (2001) (0)
Prognostic factors after relapse in non-Hodgkin's lymphoma of favorable histologic type (1980) (0)
Immunohistochemi-NCCN Diffuse Large B-Cell Lymphoma Version 1 . 2016 Clinical Practice Guidelines in Oncology (2016) (0)
Report o f a n I nternational W orkshop t o S tandardize Response C riteria f or N on-Hodgkin's L ymphomas (1999) (0)
335 Utility of imaging in cutaneous marginal zone lymphoma (2017) (0)
Improved Lung Sparing During Total Body Irradiation Using a VMAT Technique Versus a 2D Lung Block Approach: Preliminary Single-institutional Experience (2020) (0)
SHORT TANDEM REPEAT ANALYSIS TO MONITOR BONE MARROW ENGRAFTMENT IN NONHUMAN PRIMATES. (2004) (0)
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease. (2009) (0)
Non-Hodgkin's lymphoma involvement of Waldeyer's ring (1977) (0)
62 – Mycosis Fungoides (2010) (0)
Extranodal lymphoma involving the thyroid (1980) (0)
A Step Towards Making VMAT TBI More Prevalent: Automating the Treatment Planning Process. (2021) (0)
2043 Primary cutaneous lymphoma (1995) (0)
Ef fi cacy of abbreviated Stanford V chemotherapy and involved-fi eld radiotherapy in early-stage Hodgkin lymphoma : mature results of the G 4 trial † (2013) (0)
Radiation Therapy in Advanced Stage Diffuses Large B-Cell Lymphoma (2016) (0)
Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): Management in the Modern Era (2014) (0)
Use of High-Throughput Sequencing (HTS) of TCRß to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant (2014) (0)
Secondary cancers after Hodgkin’s disease: update of a cohort showing pitfalls of Kaplan-Meier projections (2002) (0)
[Radiotherapy vs. chemotherapy in early-stage Hodgkin's disease: a justified approach?]. (1992) (0)
combined modality therapy: the Stanford experience The management of stage I--II Hodgkin's disease with irradiation alone or (2011) (0)
Saturday, May 10, 2003 (S84-S102) (2003) (0)
Outcomes Of Adult Patients With Lymphoma Treated With Nonmyeloablative Total Lymphoid Irradiation For Stem Cell Transplant (SCT) Conditioning With A Boost To High Risk Or Gross Disease (2020) (0)
Principles of Radiation Therapy for Hodgkin Lymphoma (2020) (0)
Total skin electron beam therapy (TSEBT) +/− adjuvant topical nitrogen mustard (HN2) or HN2 alone as initial treatment of T2- T3 mycosis fungoides (MF) (1998) (0)
Local Radiotherapy for Early-stage Low Grade Follicular Lymphoma in the Post-PET Era (2011) (0)
No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission (2018) (0)
monoclonal antibody Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 (2011) (0)
Graft-Versus-Lymphoma Effect After Non-Myeloablative Allogeneic Transplant Induces Molecular Remission Assessed by High-Throughput Sequencing of T Cell Receptor in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome (2011) (0)
Investigating Factors Predictive of Large Cell Transformation and Outcomes From Low Grade Lymphomas. (2021) (0)
Hodgkins disease pathologic stage i ii the prognostic importance of initial sites of disease and extent of mediastinal involvement (1980) (0)
Utility of Systemic Staging in Low Grade B-Cell Lymphomas Presenting in the Skin (2017) (0)
Low Dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides (mf): Results of Three Phase 2 Clinical Trials (2014) (0)
Short Title: Survival in Follicular Lymphoma (2017) (0)
Bald and Golden Eagles of the SRP. (Annual report, 1986) (1986) (0)
Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation (2021) (0)
Craniosphud Irradiation for Acute Lymphoblastic Leukemia with Central Nervous System Disease at Diignosisz A Report from the Children's Cancer Group (1996) (0)
Investigating and modeling positron emission tomography factors associated with large cell transformation from low‐grade lymphomas (2022) (0)
769 High dose therapy and autologous bone marrow transplantation for relapsed or refractory hodgkin's disease: The impact of total body irradiation and involved field radiation therapy (1995) (0)
The Outcomes of Patients with Unfavorable Stage I-II Classic Hodgkin Lymphoma Treated with Stanford V Chemotherapy and Limited Irradiation (2018) (0)
Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease (2012) (0)
IMMUNOSUPPRESSION AND PERMANENT TRANSPLANTATION TOLERANCE ACROSS MAJOR HISTOCOMPATIBILITY BARRIERS FOLLOWING TOTAL LYMPHOID IRRADIATION (1979) (0)
Combined-modality therapy for the treatment of Hodgkin's disease. (1992) (0)
Iconography : Mycosis fungoides in young patients: Clinical characteristics and outcome (2011) (0)
Tomayto, Tomahto: Prescription Dose and Mean Heart Dose in Evaluating Cardiac Impact of IFRT for Hodgkin Lymphoma Survivors (2019) (0)
Non-Hodgkin's lymphoma (1979) (0)
VMAT TBI Technique Based on Automated Treatment Planning (2022) (0)
Analysis of Metabolic Tumor Volume in Patients Undergoing Bridging Radiotherapy Prior to CAR-T Therapy for Relapsed/Refractory Aggressive B Cell Lymphoma (2022) (0)
Prognostic indicators of laparotomy findings in CS I – II supradiaphragmatic Hodgkin's disease (HD) (1987) (0)
Epidemiology and Etiology (2003) (0)
The indolent extranodal lymphomas: What is the role of radiation therapy? (2009) (0)
Improved Organ Sparing with Autoplanned VMAT TBI. (2021) (0)
Long-Term Outcomes in 10-Year Survivors of Early-Stage Hodgkin Lymphoma (2019) (0)
Poster — Thur Eve — 38: Feasibility of a Table‐Top Total Body Irradiation Technique using Robotic Couch Motion (2014) (0)
Allogeneic Hematopoietic Cell Transplantation in Patients with Cutaneous Cytotoxic T-Cell Lymphoma (2021) (0)
Prognostic Factors, Treatment, and Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era (2014) (0)
Investigating Metabolic Response after CAR-T Therapy and Bridging Radiotherapy for Relapsed/Refractory B-Cell Lymphoma (2022) (0)
recommendations for the management of cutaneous B-cell lymphomas International Society for Cutaneous Lymphoma consensus European Organization for Research and Treatment of Cancer and (2008) (0)
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. (2023) (0)
Chapter 12 – COMBINED-MODALITY STUDIES IN THE TREATMENT OF HODGKIN'S DISEASE (1985) (0)
Total Lymphoid Irradiation for Immunosuppression (1988) (0)
Variable Interpretations of Involved-Site Radiation Therapy Guidelines by Experienced Radiation Oncologists (2014) (0)
Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience (2014) (0)
Research-Driven Radiation Oncology: A Narrative on the Ongoing Legacy of Henry S. Kaplan (2021) (0)
Incorporation of PET scanning into contemporary management programs for Hodgkin's disease (2009) (0)
Gonadal-sparing Total Body Irradiation (TBI) Using a VMAT Technique: Preliminary Report in Both Genders (2020) (0)
Combined modality therapy in the management of bulky mediastinal Hodgkin's disease (1990) (0)
2166 Long-term outcome after first relapse for patients who received primary radiation therapy at Stanford University for stage I and II low grade follicular lymphomas (1997) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard T. Hoppe?

Richard T. Hoppe is affiliated with the following schools:

Richard T. Hoppe's Academic­Influence.com Rankings

Richard T. Hoppe's Degrees

Similar Degrees You Can Earn

Why Is Richard T. Hoppe Influential?

Richard T. Hoppe's Published Works

Published Works

What Schools Are Affiliated With Richard T. Hoppe?

Richard T. Hoppe's AcademicInfluence.com Rankings